6-amino-2-oxaadamantan-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 6-amino-2-oxaadamantan-1-ol
• 英文别名: 6-Amino-2-oxatricyclo[3.3.1.13,7]decan-1-ol；6-amino-2-oxatricyclo[3.3.1.13,7]decan-1-ol
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: CYZWWKTTYUCWBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-amino-2-oxaadamantan-1-ol 、 氯贝酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 生成 2-(4-Chloro-phenoxy)-N-(1-hydroxy-2-oxa-tricyclo[3.3.1.1^3,7]dec-6-yl)-2-methyl-propionamide
  参考文献：
  名称：

  Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements

  摘要：

  A series of structurally novel and metabolically stable bridged bicyclic carbocycle and heterocycle adamantane replacements have been synthesized and biologically evaluated. Several of these compounds exhibit excellent human and mouse 11 beta-HSD1 potency and 11 beta-HSD2 selectivity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.062
• 作为产物：
  描述：

  Bicyclo-<3.3.1>nonane-3,7,9-trion-9-(ethylen)-acetal 在 palladium on activated charcoal sodium tetrahydroborate 、 氨 、 氢气 作用下， 以 甲醇 为溶剂， 反应 63.0h， 生成 6-amino-2-oxaadamantan-1-ol
  参考文献：
  名称：

  Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements

  摘要：

  A series of structurally novel and metabolically stable bridged bicyclic carbocycle and heterocycle adamantane replacements have been synthesized and biologically evaluated. Several of these compounds exhibit excellent human and mouse 11 beta-HSD1 potency and 11 beta-HSD2 selectivity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.062

文献信息

• COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION
  申请人：Xu Lifeng

  公开号：US20140045779A1

  公开（公告）日：2014-02-13

  This invention relates with anti-tumor activities of new compounds containing an adamantyl group or analogs thereof. The invention also relates with the medication applications of anti-tumor and other diseases by this kind of compounds with the combination of S, P, T structures containing adamantyl group and the formation of stereoisomer, tautomers, prodrug, pharmaceutically acceptable salts, complex salts or solvates to their anticancer application and anticancer agents, which have the following general formula:

  这项发明涉及含有金刚烷基团或其类似物的新化合物的抗肿瘤活性。该发明还涉及利用这种含有金刚烷基团的S、P、T结构的化合物与立体异构体、互变异构体、前药、药用盐、复杂盐或溶剂化物的结合来治疗抗肿瘤和其他疾病的药物应用，这些抗肿瘤剂具有以下一般公式：
• Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements
  作者：Vince S.C. Yeh、Ravi Kurukulasuriya、David Madar、Jyoti R. Patel、Steven Fung、Katina Monzon、William Chiou、Jiahong Wang、Peer Jacobson、Hing L. Sham、J.T. Link

  DOI：10.1016/j.bmcl.2006.07.062

  日期：2006.10

  A series of structurally novel and metabolically stable bridged bicyclic carbocycle and heterocycle adamantane replacements have been synthesized and biologically evaluated. Several of these compounds exhibit excellent human and mouse 11 beta-HSD1 potency and 11 beta-HSD2 selectivity. (c) 2006 Elsevier Ltd. All rights reserved.